The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis.
Miguel CarracedoSven-Christian PawelzikGonzalo ArtiachMarianne G PouwerOscar PlundePeter Saliba-GustafssonEwa EhrenborgPer ErikssonElsbet PietermanLeif StenkeHans M G PrincenAnders Franco-CerecedaMagnus BäckPublished in: British journal of pharmacology (2022)
These findings suggest that inhibition of DDR2 by nilotinib promoted aortic valve thickening and VIC calcification, with possible translational implications for cardiovascular surveillance and possible personalized medicine in CML patients.
Keyphrases
- aortic valve
- transcatheter aortic valve replacement
- transcatheter aortic valve implantation
- aortic valve replacement
- aortic stenosis
- end stage renal disease
- ejection fraction
- chronic kidney disease
- chronic myeloid leukemia
- newly diagnosed
- public health
- peritoneal dialysis
- prognostic factors
- heart failure
- patient reported outcomes
- left ventricular
- coronary artery disease